Pembrolizumab in HER2-Positive Gastric Cancer
New England Journal of Medicine · 10.10.2024 · 391 (14) · 1360-1362
DOI: 10.1056/nejmc2408121 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 10.10.2024. Verfasst von Yelena Y Janjigian und 25 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY janjigiy@mskcc.org. Hauptthemen laut MEDLINE: Adenocarcinoma, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 2 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Merck & Co., Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, NY janjigiy@mskcc.org.
- National Cancer Hospital East, Kashiwa, Japan.
- Harbin Medical University Cancer Hospital, Harbin, China.
- Fifth Medical Center of the People's Liberation Army, Beijing, China.
- Istituto Oncologico Veneto, Padua, Italy.
- University Hospital of Brest, Brest, France.
ORCID-Profile: Akihito Kawazoe, Kohei Shitara
Förderung
- NCI NIH HHS
- NIH HHS
- Merck & Co., Inc
- Memorial Sloan Kettering Cancer Center National Institutes of Health/National Cancer Institute Cancer Center Support Grant
Zitieren
APA
Janjigian, Y. Y., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J. P., Yañez, P., Wyrwicz, L. S., Shen, L., Ostapenko, Y., Bilici, M., Chung, H. C., Shitara, K., Qin, S., Van Cutsem, E., Tabernero, J., Luo, S., Mahave, M., Tang, Y., …, & Rha, S. Y. (2024). Pembrolizumab in HER2-Positive Gastric Cancer. New England Journal of Medicine, 391(14), 1360-1362. https://doi.org/10.1056/nejmc2408121
Vancouver
Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab in HER2-Positive Gastric Cancer. New England Journal of Medicine. 2024;391(14):1360-1362. doi:10.1056/nejmc2408121
BibTeX
@article{Janjigian2024,
author = {Janjigian, Yelena Y and Kawazoe, Akihito and Bai, Yuxian and Xu, Jianming and Lonardi, Sara and Metges, Jean Phillipe and Yañez, Patricio and Wyrwicz, Lucjan S and Shen, Lin and Ostapenko, Yuriy and Bilici, Mehmet and Chung, Hyun Cheol and Shitara, Kohei and Qin, Shukui and Van Cutsem, Eric and Tabernero, Josep and Luo, Suxia and Mahave, Mauricio and Tang, Yong and Lowery, Maeve and Monteiro, Maria M F and Xu, Linzhi and Shih, Chie-Schin and Sharan, Kanu P and Bhagia, Pooja and Rha, Sun Young},
title = {Pembrolizumab in HER2-Positive Gastric Cancer},
journal = {New England Journal of Medicine},
year = {2024},
volume = {391},
number = {14},
pages = {1360--1362},
doi = {10.1056/nejmc2408121}
}
EUVIMED